Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Multiple Myeloma
Interventions: Vorinostat, Lenalinomide and Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Seasonal Influenza
Interventions: mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 22
States / cities: Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Interventions: EsoCheck®, EsoGuard®; Device · Diagnostic Test
Lead sponsor: Lucid Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Age-Related Macular Degeneration
Interventions: Retinal Imaging; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Fargo, North Dakota • Erie, Pennsylvania + 5 more

Conditions: Otitis Media
Interventions: ear pain counseling, language power counseling; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 15 Months
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Zolpidem (SL800750); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 2 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 3
States / cities: Bethesda, Maryland • Research Triangle Park, North Carolina • Madison, Wisconsin

Conditions: Colo-rectal Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacokinetics, Cardiopulmonary Bypass, Children
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Up to 2 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aging
Interventions: vaccine; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Skin Infections, Bacterial
Interventions: Retpamulin Ointment, 1%, Linezolid; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 2 Months and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more

Conditions: Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions: Cortical Bone Mechanics Technology; Diagnostic Test
Lead sponsor: Ohio University; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 394 participants
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more

Conditions: Solid Tumours
Interventions: selumetinib (oral); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Migraine Prophylaxis
Interventions: Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 35
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more

Conditions: Hepatocellular Carcinoma
Interventions: Lenvatinib, Transcatheter Arterial Chemoembolization; Drug · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: WHIM Syndrome
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more

Conditions: Respiratory Syncytial Viruses
Interventions: Lumicitabine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 36 Months
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more

Conditions: Sleep Quality, Sleep and Circadian Problems
Interventions: Olly melatonin-free supplement, Placebo Supplement; Dietary Supplement
Lead sponsor: Olly, PBC; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Transplants
Interventions: Intervention 1 - SRTR (age question 1st), Intervention 2 - SRTR (BMI question 1st), Intervention 3 - TCST (age question 1st), Intervention 4 - TCST (BMI question 1st); Other
Lead sponsor: Ajay Israni, MD; Other
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity, Childhood
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 9 Years to 11 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Visual Acuity
Interventions: JJVC Fitting Guides; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Bone Diseases
Interventions: Vitoss; Device
Lead sponsor: Orthovita d/b/a Stryker; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Potentially Inappropriate Medications
Interventions: EHR-based "nudge" interventions; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 65 Years and older
Enrollment: 8,640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: Diet 1, Diet 2; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Lucid Registry Study

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

The Pediatric Sleep Study

Creating a Patient-centered Report Card for Solid Organ Transplant Candidates

Impact of Hypothalamic Gliosis on Appetite Regulation and Obesity Risk in Children

Clinical Evaluation of Fitting Investigational Contact Lenses

Evaluation of Vitoss With and Without BMA for Benign Cavitary Lesions

An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System

Diet Interventions in Psoriatic Arthritis